Drug Discovery – Frost Institute for Data Science & Computing

Patenting 101: Intellectual Property Considerations in AI 5/9

The Miami CTSI (Clinical and Translational Science Institute) C2C: Concept to Commercialization Series presents Paul Tanpitukpongse, JD, principal and patent attorney at Meunier Carlin & Curfman, LLC, in Atlanta, Georgia for a talk on “Patenting 101: Intellectual Property Considerations in Artificial Intelligence” on Tuesday, May 9, 2023, from 12:00 to 1:00 PM via Zoom. Read more “Patenting 101: Intellectual Property Considerations in AI 5/9” →

News

UM IDSC Partners with Tel Aviv University on Data…

A new international partnership between IDSC and Tel Aviv University in Israel will open the door to collaborative research, learning, and cultural initiatives. “We are looking forward to creating exciting opportunities for our researchers, faculty, and students, to expand their horizons,” said Nick Tsinoremas, IDSC Founding Director, who recently signed a memorandum of understanding with Tel Aviv University (TAU). Read more “UM IDSC Partners with Tel Aviv University on Data Science” →

Publications

Machine and Deep Learning Approaches for Cancer Drug Repurposing

In past years, medical oncology has witnessed an unprecedented explosion in the understanding of cancer pathophysiology and pathogenesis. With the advancement of next-generation sequencing technologies such as single-cell RNA sequencing, we are better equipped to explore and model complex phenomena such as cancer heterogeneity, resistance, and etiologies at a granular level. Read more “Machine and Deep Learning Approaches for Cancer Drug Repurposing” →

Publications

Research Techniques Made Simple: Molecular Docking in Dermatology-A Foray…

Drug discovery is a complex process with many potential pitfalls. To go to market, a drug must undergo extensive preclinical optimization followed by clinical trials to establish its efficacy and minimize toxicity and adverse events. The process can take 10-15 years and command vast research and development resources costing over $1 billion. Read more “Research Techniques Made Simple: Molecular Docking in Dermatology-A Foray into In Silico Drug Discovery” →

Publications

Structural Interactions of Resveratrol With Its Bandwagon of Targets

Resveratrol (3, 4′, 5-trihydroxy-trans-stilbene) is a natural phytoalexin found in grapes and has long been thought to be the answer to the “French Paradox.” There is no shortage of preclinical and clinical studies investigating the broad therapeutic activity of resveratrol. However, in spite of many comprehensive reviews published on the bioactivity of resveratrol, Read more “Structural Interactions of Resveratrol With Its Bandwagon of Targets” →

Events - Past

Human vs. Machine-Enhanced Discovery

Join Mark Musen (Stanford), Janice Kranz and Stephan Schürer (University of Miami) for CDD’s Q3 Town Hall Webinar, “Human vs. Machine-Enhanced Scientific Discovery.” We’re seeing ‘Big Data’ everywhere: healthcare, business, sports, traffic control, biology, drug discovery. The ‘behind-the-scenes’ tool enabling the power of Big Data – searching, sharing, visualizing, querying, analyzing – is the Semantic Web (aka ‘Web 3.0’ a term coined by Tim Berners-Lee in a Scientific American article (http://www.scientificamerican.com/article/the-semantic-web/) in 2001 to describe a web of data that can be processed by machines.) . The major advancement brought about by the Semantic Web is the treatment of data and metadata on the internet as one giant graph of knowledge. Instead of the disjointed islands of knowledge we are used to, with the Semantic Web, databases will be more naturally connected to one other (except where privacy prevents openness). Read more “Human vs. Machine-Enhanced Discovery” →

News - Archived

BD2K-LINCS Summer Research Training Program

The 2015 Summer Research Training Program (June 1-August 7, 2015) in Biomedical Big Data Science sponsored by the Big Data to Knowledge (BD2K) Data Coordination and Integration Center (DCIC) for the Library of Integrated Network-based Cellular Signatures (LINCS) is a research-intensive, 10-week training program offered at six sites affiliated with our NIH-funded BD2K Center: Read more “BD2K-LINCS Summer Research Training Program” →

Grants

NIH Big Data to Knowledge (BD2K) Grant

Stephan Schürer, PhD, Associate Professor of Molecular and Cellular Pharmacology at the Miller School, and Chemoinformatics program leader at IDSC, is the head of the team of University of Miami researchers funded through the National Institutes of Health (NIH) who are creating a Data Coordination and Integration Center for the Library of Integrated Network-based Cellular Signatures (LINCS) program. Read more “NIH Big Data to Knowledge (BD2K) Grant” →

Publications

Allosteric Inhibition of the IRE1α RNase Preserves Cell Viability…

Depending on endoplasmic reticulum (ER) stress levels, the ER transmembrane multidomain protein IRE1α promotes either adaptation or apoptosis. Unfolded ER proteins cause IRE1α lumenal domain homo-oligomerization, inducing trans autophosphorylation that further drives homo-oligomerization of its cytosolic kinase/endoribonuclease (RNase) domains to activate mRNA splicing of adaptive XBP1 transcription factor. Read more “Allosteric Inhibition of the IRE1α RNase Preserves Cell Viability and Function during Endoplasmic Reticulum Stress” →

News - Archived

New Release of the LIFE Search Engine

A new version of the LIFE search engine has been released. LIFE makes it possible to search across data generated at the LINCS project. This new release includes recent data releases from the LINCS Consortium. It has improved search functionality and several new data visualization features. Read more “New Release of the LIFE Search Engine” →

n>Drug Discovery